Market Research Logo

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016’, provides an overview of the Human papillomavirus (HPV) Associated Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer
    • The report reviews pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Human papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects
    • The report assesses Human papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Human Papillomavirus (HPV) Associated Cancer Overview
    Therapeutics Development
    Pipeline Products for Human Papillomavirus (HPV) Associated Cancer - Overview
    Pipeline Products for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis
    Human Papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies
    Human Papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes
    Human Papillomavirus (HPV) Associated Cancer - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Human Papillomavirus (HPV) Associated Cancer - Products under Development by Companies
    Human Papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes
    Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development
    Admedus Ltd
    Advaxis, Inc.
    Antigen Express, Inc.
    Bionor Pharma ASA
    BioNTech AG
    Cancer Research Technology Limited
    Cell Medica Limited
    Etubics Corporation
    EyeGene, Inc.
    Formune S.L.
    Genexine, Inc.
    Genticel S.A.
    iBio, Inc.
    Immunovaccine, Inc.
    Inovio Pharmaceuticals, Inc.
    Inthera Bioscience AG
    Johnson & Johnson
    Karyopharm Therapeutics, Inc.
    Kite Pharma, Inc.
    MedImmune, LLC
    Novartis AG
    Onconova Therapeutics, Inc.
    Oryx GmbH & Co. KG
    Profectus BioSciences, Inc.
    Selecta Biosciences, Inc.
    Shantha Biotechnics Limited
    Sirnaomics, Inc.
    Theravectys SA
    THEVAX Genetics Vaccine USA Inc
    Tomegavax, Inc.
    Transgene SA
    UbiVac, LLC
    Vaccibody AS
    Vault Pharma Inc.
    Virometix AG
    ViroStatics srl
    VLPbio
    Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    ABI-1968 - Drug Profile
    AEH-10p - Drug Profile
    alpelisib - Drug Profile
    Antibodies to Target E6 for HPV Associated Cancer - Drug Profile
    Antibodies to Target E7 for HPV Associated Cancer - Drug Profile
    BVAC-C - Drug Profile
    Cellular Immunotherapy for HPV Associated Cancers - Drug Profile
    Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile
    Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile
    CerviVax - Drug Profile
    CMD-004 - Drug Profile
    DPV-001 - Drug Profile
    DPXE-7 - Drug Profile
    EDA-HPVE7 - Drug Profile
    EG-HPV - Drug Profile
    Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile
    ETBX-041 - Drug Profile
    GTL-001 - Drug Profile
    GTL-002 - Drug Profile
    GX-188E - Drug Profile
    human papillomavirus (7-valent) vaccine - Drug Profile
    human papillomavirus [Serotype 16] vaccine - Drug Profile
    human papillomavirus [serotypes 16] vaccine - Drug Profile
    human papillomavirus vaccine - Drug Profile
    human papillomavirus vaccine - Drug Profile
    human papillomavirus vaccine - Drug Profile
    human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile
    INO-3106 - Drug Profile
    INO-3112 - Drug Profile
    Lm-LLO-ISG15 - Drug Profile
    LN-145 - Drug Profile
    Monoclonal Antibody to Target E6 and E7 Proteins for Oncology - Drug Profile
    NIT-02 - Drug Profile
    NP-001 - Drug Profile
    PVX-01 - Drug Profile
    Recombinant Vector Vaccine to Target E7 for HPV Associated Cancers - Drug Profile
    Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile
    rigosertib sodium - Drug Profile
    sdCMV-002 - Drug Profile
    SEL-701 - Drug Profile
    Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile
    Small Molecules for Solid Tumors and HPV Associated Cancer - Drug Profile
    STP-909 - Drug Profile
    Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile
    Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile
    TA-CIN - Drug Profile
    TG-4001 - Drug Profile
    TVGV-1 - Drug Profile
    Vacc-HPV - Drug Profile
    Vaccine for HIV and HPV Associated Cancer - Drug Profile
    Vaccine for HPV Associated Cancer - Drug Profile
    Vaccine for HPV Associated Cancers - Drug Profile
    Vaccine for HPV Associated Cervical Cancer - Drug Profile
    Vaccine for HPV Associated Cervical Cancer - Drug Profile
    Vaccine for HPV Associated Cervical Cancer - Drug Profile
    Vaccine for HPV Associated Skin Cancer - Drug Profile
    Vaccine for Human papillomavirus Associated Cervical Cancer - Drug Profile
    VB-1016 - Drug Profile
    verdinexor - Drug Profile
    VGX-3100 - Drug Profile
    Vicoryx - Drug Profile
    VMT-2 - Drug Profile
    VPI-241 - Drug Profile
    Vvax-001 - Drug Profile
    Human Papillomavirus (HPV) Associated Cancer - Dormant Projects
    Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2016
    Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Investigation by Universities/Institutes, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma ASA, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech AG, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Limited, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cell Medica Limited, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corporation, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Formune S.L., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genexine, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genticel S.A., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by iBio, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Immunovaccine, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inthera Bioscience AG, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Johnson & Johnson, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune, LLC, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Novartis AG, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Limited, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys SA, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Tomegavax, Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by UbiVac, LLC, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vault Pharma Inc., H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by ViroStatics srl, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Pipeline by VLPbio, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H2 2016
    Human Papillomavirus (HPV) Associated Cancer - Dormant Projects (Contd..1), H2 2016
    List of Figures
    Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2016
    Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Top 10 Routes of Administration, H2 2016
    Number of Products by Stage and Top 10 Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report